Novel mmp-2 derivatives for use as inhibitors of integrin .alpha.v.beta.3
CA 2421283 A1 · Owner: Diefenbach, Beate · Inventors: Groth, Ulrich; Diefenbach, Beate; Jonczyk, Alfred
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to novel compounds of the formula (I) which are , biologically active as the ligands of integrin .alpha.~V.beta.~3and wherein X represents H, an acyl or a peptide fragment of 1 to 20 amino acids selected , from the list of the naturally occurring amino acids Y represents a peptide , fragment selected from the sequence range 466-660 of human Pro-MMP-2 Z , represents OH, NH~2, NHA, NA~2 or a peptide fragment of 1 to 20 amino acids selected from the list of the naturally occurring amino acids A represents an , alkyl having 1-10 C atoms and acyl represents an alkanoyl having 1-10 C atoms, wherein the primary amino groups can be also provided with conventional amine …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 28, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.